Cutaneous T-Cell Lymphoma (CTCL)
Also known as: Cutaneous T-Cell Lymphomas / Cutaneous T Cell Lymphoma / Cutaneous T-Cell Lymphoma / Cutaneous T Cell Lymphomas (CTCL) / Cutaneous T Cell Lymphoma (CTCL) / CTCL / Primary cutaneous T-cell lymphoma (morphologic abnormality) / Cutaneous T-cell lymphoma (morphologic abnormality) / Primary cutaneous T-cell lymphoma (disorder) / Lymphoma, T-Cell, Cutaneous / Cutaneous lymphoma (disorder)
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB00242 | Cladribine | A purine antimetabolite used for the management of relapsing forms of Multiple Sclerosis (MS), used in patients who have not responded to or who were unable to tolerate alternative MS drugs. |
| DB00004 | Denileukin diftitox | A recombinant cytotoxic protein based on a combination of diphtheria toxin fragments and interleukin-2 used to treat cutaneous T-cell lymphoma by targeting the interleukin-2 receptor. |
| DB00441 | Gemcitabine | A nucleoside metabolic inhibitor used as adjunct therapy in the treatment of certain types of ovarian cancer, non-small cell lung carcinoma, metastatic breast cancer, and as a single agent for pancreatic cancer. |
| DB00034 | Interferon alfa-2a | A form of recombinant human interferon used to stimulate the innate antiviral response in the treatment of hepatitis B and C viruses. |
| DB00553 | Methoxsalen | A furocoumarin used to treat psoriasis and vitiligo. |
| DB06813 | Pralatrexate | An antineoplastic agent used for the treatment of relapsed or refractory peripheral T-cell lymphoma. |
| DB06176 | Romidepsin | A histone deacetylase (HDAC) inhibitor used to treat cutaneous T-cell lymphoma. |